A
884.30
9.33 (1.07%)
| Penutupan Terdahulu | 874.97 |
| Jumlah Dagangan | 144,565 |
| Harga / Pendapatan (P/E Ke hadapan) | 26.75 |
| Harga / Jualan (P/S) | 9.97 |
| Harga / Buku (P/B) | 6.63 |
| Julat 52 Minggu |
| Margin Keuntungan | 40.26% |
| Margin Operasi (TTM) | 17.50% |
| EPS Cair (TTM) | 16.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 95.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.71% |
| Nisbah Semasa (MRQ) | 7.29 |
| Aliran Tunai Operasi (OCF TTM) | -82.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -143.39 M |
| Pulangan Atas Aset (ROA TTM) | -0.21% |
| Pulangan Atas Ekuiti (ROE TTM) | 17.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | argenx SE | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.2 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -5.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -1.11 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Institusi | 55.54% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |